Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03133221 · ClinicalTrials.gov registry record · Phase 2
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03133221 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 17 participants.
The verdict
NCT03133221, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).
Interventions
- DRUG Zydelig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2024-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03133221
The ClinicalTrials.gov registry entry for NCT03133221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zydelig is the first listed.
NCT03133221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03133221 about?
NCT03133221 is a clinical study titled "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation". This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).
What is the current status of trial NCT03133221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-10-23. Estimated completion is 2024-09-29.
What interventions are being tested in trial NCT03133221?
The interventions under investigation include: Zydelig (DRUG).
Who is sponsoring clinical trial NCT03133221?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.